PacRim Breast and Prostate Cancer Meeting Series

The international Pacific Rim (PacRim) meetings focus on contemporary issues in breast and prostate cancer research with a view to improving disease outcomes and developing strategies for prevention and improved quality of life.

The goal of PacRim meetings is to identify and address critical issues in breast and prostate cancer to progress the field and stimulate cutting-edge research into these two common diseases. Introductory talks are short and designed to set the stage for robust, in-depth discussions rather than reporting data in the traditional sense. The relatively small size (100 – 150 participants) and unique think-tank format of PacRim meetings ensures a lively interaction and extensive discussion between participants comprising scientists, clinicians and both industry and research foundation representatives of international standing. A key objective is to foster innovative collaborative research networks that will lead to new insight, better treatments and ultimately improved patient outcomes.

The foundation PacRim meeting organising institutions are the Dame Roma Mitchell Cancer Research Laboratories (DRMCRL) at the University of Adelaide, Australia; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, USA; Garvan Institute for Medical Research, Sydney, Australia; Vancouver Prostate Centre, Vancouver, Canada; Hanson Institute, Adelaide;  University of Washington and Fred Hutchinson Cancer Research Center, Seattle, USA.

PacRim meetings were inspired by the Hormones and Cancer 2000 Meeting held in Port Douglas, Australia after the Sydney 2000 Olympic Games and take place every two to three years.  There have been seven PacRim meetings, which have facilitated the establishment of international networks across Australia, Canada, the Americas and the broader Asia-Pacific. The 8th PacRim Breast and Prostate Cancer Meeting will be held in 2024. This meeting will celebrate the 21st anniversary of the PacRim meeting series and has been confirmed for August. More details to follow.